Definium Therapeutics, Inc. (DFTX)
| Market Cap | 5.51B +634.7% |
| Revenue (ttm) | n/a |
| Net Income | -353.79M |
| EPS | -3.48 |
| Shares Out | 134.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,803,107 |
| Open | 43.18 |
| Previous Close | 43.82 |
| Day's Range | 40.85 - 43.38 |
| 52-Week Range | 8.70 - 49.70 |
| Beta | 2.26 |
| Analysts | Strong Buy |
| Price Target | 67.47 (+64.64%) |
| Earnings Date | Aug 6, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $67.47, which is an increase of 64.64% from the latest price.
News
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $75 price target The company’s lead asset, DT120 – LSD – is in pivotal studies…
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics announces results from Phase 3 study of DT120
Definium Therapeutics (DFTX) announced positive topline results from Voyage, its first Phase 3 study of DT120 Orally Disintegrating Tablet, ODT, 100 microgram in adults with generalized anxiety disord...
Definium Therapeutics price target raised to $70 from $60 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $60 and keeps an Outperform rating on the shares.
Definium Therapeutics price target raised to $66 from $50 at Needham
Needham raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $50 and keeps a Buy rating on the shares.
RBC Capital boosts Definium price target, says opportunity will be robust
RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an Outperform rating on the shares following “strong” Voyage study data. While RBC…
Definium Therapeutics price target raised to $75 from $57 at Baird
Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $75 from $57 and keeps an Outperform rating on the shares. The firm updated its model following positive results…
Definium Therapeutics price target raised to $64 from $58 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $64 from $58 and keeps a Buy rating on the shares. The firm updated its model…
Definium Therapeutics price target raised to $90 from $74 at Jones
Jones raised the firm’s price target on Definium Therapeutics (DFTX) to $90 from $74 and keeps a Buy rating on the shares. The company announced that the Phase III VOYAGE…
Definium Therapeutics price target raised to $66 from $57 at RBC Capital
RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an Outperform rating on the shares. Following the company’s call with more details,…
Definium Therapeutics price target raised to $55 from $50 at Maxim
Maxim raised the firm’s price target on Definium Therapeutics (DFTX) to $55 from $50 and keeps a Buy rating on the shares. The firm cites the company having announced topline…
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Definium Therapeutics Transcript: Study result
The phase III Voyage study of DT120 in GAD met all primary and key secondary endpoints, showing rapid, robust, and durable efficacy with a large effect size and favorable safety profile. Benefits were consistent across subgroups, and long-term data support sustained improvement with intermittent dosing.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on August 12, 2026, disclosing material business information to investors.
Definium Therapeutics Slides: Study result
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Earnings Call Transcript: Q2 2026
Phase III results for DT120 ODT in MDD showed unprecedented efficacy and tolerability, with pivotal GAD data imminent. Strong financials, including $1.1B in cash, support ongoing R&D and commercial launch preparations, positioning the company for long-term growth.
Definium Therapeutics Earnings release: Q2 2026
Definium Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Definium Therapeutics Quarterly report: Q2 2026
Definium Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)
of June 30, 2026, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of approximately $1.1 billion compared to $411.6 million as of December 31, 2025. Based on the Company’s…
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics initiated with an Overweight at Wells Fargo
Wells Fargo analyst Benjamin Burnett initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $68 price target The firm believes Spravato validates the interventional psychiatr...
Definium Therapeutics price target raised to $73 from $48 at Piper Sandler
Piper Sandler raised the firm’s price target on Definium Therapeutics (DFTX) to $73 from $48 and keeps an Overweight rating on the shares. The firm says its thinking is not…